IL-1β和iNOS可以驱动喘并发症和长期过敏鼻炎儿童的肺功能下降.
Myung Woul Han1, Song Hee Kim2, Inbo Oh3
1Department of Otolaryngology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. brightmoon@uuh.ulsan.kr.
概括
介质素-1β (IL-1β) 和可诱导的氧化合成酶 (iNOS) 表明患有多年性过敏性鼻炎 (PAR) 的儿童患有喘并发症. 较高水平与肺功能下降相关,这表明早期干预目标.
科学领域:
- 免疫学 免疫学 免疫学
- 儿科过敏 儿科过敏
- 呼吸系统医学 呼吸系统医学
背景情况:
- 过敏性鼻炎 (AR) 和喘经常同时存在,需要早期检测这种并发症.
- 识别早期指标可以促进及时治疗,并预防AR患者的喘进展.
- 长期过敏性鼻炎 (PAR) 影响儿童,其中一小部分患有喘.
研究的目的:
- 调查介素-1β (IL-1β) 和可诱导的氧化合成酶 (iNOS) 在PAR-喘并发症中的作用.
- 评估IL-1β和iNOS与PAR儿童肺功能之间的关联.
- 在韩国儿童中探索生物标志物,包括IL-1β,iNOS和上皮介质转变 (EMT) 标志物.
主要方法:
- 分析了一组240名韩国儿童 (6-10岁) 患有PAR (单独PAR与PAR对比) 的队列. 帕尔和喘).
- 使用ELISA测量了IL-1β,CCL-24,E-cadherin和vimentin的血清水平.
- 使用NOS套件量化了表皮 iNOS,并检查了血液中的乙氨基和IgE.
主要成果:
- 血清IL-1β,iNOS和维丁水平升高是PAR-喘并发症的重要指标.
- 较高的IL-1β,iNOS和维门丁度与PAR儿童的肺功能下降相关.
- 与E-cadherin,vimentin和CCL-24相关的IL-1β表达;在IL-1β和iNOS之间没有发现相关性.
结论:
- IL-1β 和 iNOS 作为 PAR-喘进展和肺功能下降的潜在生物标志物.
- 这些生物标志物表明了儿科呼吸道疾病早期干预策略的可能目标.
- 快速识别这些标志物可能有助于预防PAR儿童喘的发展.
关键词:
过敏性鼻炎是一种过敏性鼻炎.喘 喘 是一种伴随性疾病 伴随性疾病这是E-cadherin.皮质 - 介质细胞过渡.一个IL-1ββ.在Vimentin中,使用了Vimentin.我们的 iNOS iNOS更多相关视频
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
10.4K
11:54Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
30.3K
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:20Asthma: Pathogenesis and Management
405
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
405
01:19Antiasthma Drugs: Leukotriene Modifiers
306
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
306
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:17Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
301
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
301